Department of Digestive Surgical Oncology - Liver Transplantation Unit, CHU Besancon, France3 Boulevard Alexandre Fleming, 25000, Besançon Cedex, France.
Department of Endocrinology, CHU Besancon, France.
BMC Surg. 2024 Sep 14;24(1):264. doi: 10.1186/s12893-024-02534-9.
After total thyroidectomy (TT), postoperative hypoparathyroidism (PH) is the most frequent complication. Yet, management strategies for PH remain disputed. The aim of this study was to evaluate outcomes of a reactive supplementation in case of symptomatic PH. Additionally, risk factors for symptomatic PH and readmission due to PH were analyzed.
All consecutive patients who underwent TT or completion from 2017 to 2022 were considered for inclusion. During this period, a reactive to symptom vitamin-calcium supplementation was used. The primary outcome was the occurrence of severe PH after discharge resulting in readmission.
Overall, 307 patients were included, of which 98 patients (31.9%) developed symptomatic PH including 43 patients before discharge. Independent risk factors for developing symptomatic PH were age (p = 0.010) and postoperative day 1 (POD1) PTH level (p < 0.001). Overall, 264 patients (86%) did not present PH before discharge and were discharged home. Among them, 55 patients (20.8%) experienced symptomatic PH, requiring readmission in 18 patients. The overall readmission rate owing to symptomatic PH requiring intravenous supplementation despite oral vitamin-calcium supplementation was 6.8% (n = 18). Independent risk factors for symptomatic PH-related readmission were age (p = 0.007) and POD1 PTH level (p < 0.001). Adequate cut-off values for predicting readmission were POD1 albumin-adjusted calcium = 2.1 mmol/l (Sensibility = 0.95, Specificity = 0.30) and POD1 PTH = 11.5 pg/ml (Sensibility = 0.90, Specificity = 0.71).
Supplementing only symptomatic patients was safe and efficient. This attitude does not alter on morbidity, mortality or readmission rate which is in line with current literature.
全甲状腺切除术后(TT),甲状旁腺功能减退症(PH)是最常见的并发症。然而,PH 的管理策略仍存在争议。本研究旨在评估在有症状 PH 的情况下进行反应性补充的结果。此外,还分析了发生症状性 PH 和因 PH 再次入院的风险因素。
所有 2017 年至 2022 年期间接受 TT 或完成 TT 的连续患者均被纳入研究。在此期间,使用反应性对症维生素-钙补充剂。主要结局是出院后发生严重 PH 导致再次入院。
共纳入 307 例患者,其中 98 例(31.9%)发生症状性 PH,其中 43 例发生在出院前。发生症状性 PH 的独立危险因素是年龄(p=0.010)和术后第 1 天(POD1)甲状旁腺激素水平(p<0.001)。总体而言,264 例(86%)患者在出院前未出现 PH,并出院回家。其中,55 例(20.8%)患者出现症状性 PH,18 例患者需要再次入院。尽管进行了口服维生素-钙补充,但由于症状性 PH 需要静脉补充而导致的总再入院率为 6.8%(n=18)。症状性 PH 相关再入院的独立危险因素是年龄(p=0.007)和 POD1 甲状旁腺激素水平(p<0.001)。预测再入院的合适截断值为 POD1 白蛋白校正钙=2.1mmol/l(灵敏度=0.95,特异性=0.30)和 POD1 甲状旁腺激素=11.5pg/ml(灵敏度=0.90,特异性=0.71)。
仅对有症状的患者进行补充是安全有效的。这种方法不会改变发病率、死亡率或再入院率,与当前文献一致。